High materiality7/10
Dyne Therapeutics (DYN) PT Lowered to $37 at Raymond James
Why it may matterVerify against the original reporting
Upside potential remains despite target cut.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
PT lowered to $37 from prior, but remains above current price, implying upside.
- PT lowered to $37; current price $20.47; upside implied.
Key facts
- 01
Target: $37
- 02
Posted price: $20.47
- 03
Analyst firm: Raymond James
- 04
Analyst: Michael Freeman
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.